Morgan Stanley: BABA-SW (09988) rated "outperform" with a target price lowered to HKD 126.4.
Morgan Stanley has lowered its earnings per share forecast for Alibaba-SW (09988) for the fiscal years 2024 and 2025 by 3% and 5% respectively, in order to reflect a conservative outlook on the consumer market.
"Morgan Stanley released a research report stating that the quarterly performance of BABA-SW (09988) until the end of September met market expectations, with stable upward trends in its main operating data. However, the company announced that it will no longer pursue the comprehensive spin-off of its cloud intelligence business due to chip restrictions and that Hema will also postpone its IPO. These news will restrict short-term upward potential and reverse recent catalysts. Morgan Stanley has removed Alibaba's Hong Kong shares from its selected list and changed the rating to "outperform the market," with the target price lowered from HKD 145.8 to HKD 126.4. The bank has also lowered the earnings forecast per share by 3% and 5% for the fiscal years 2024 and 2025, respectively, reflecting a cautious view on the consumer market."
Related Articles
SUN HUNG KAI CO (00086) repurchased 30,000 shares for HK$115,600 on November 6.
The National Development and Reform Commission convened a general scheduling meeting on the construction of major projects under the "Six Networks."
PW MEDTECH (01358) repurchased 188,000 shares on November 6 for approximately HK$164,600.
SUN HUNG KAI CO (00086) repurchased 30,000 shares for HK$115,600 on November 6.
The National Development and Reform Commission convened a general scheduling meeting on the construction of major projects under the "Six Networks."
PW MEDTECH (01358) repurchased 188,000 shares on November 6 for approximately HK$164,600.
